Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lunai Bioworks Inc.RENB · Entity 7981 | Interim CFO | November 04, 2024 | November 06, 2024 |
| Onconetix, Inc.ONCO · Entity 8471 | Director | August 15, 2025 | August 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lunai Bioworks Inc.
Report date November 04, 2024 · Filed November 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase shares of common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.62 · Expires 2034-11-04 | Direct | 58,500 |
Reported balance
After 2024-11-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-11-04 · Grant · Acquired 58,500 · Balance 58,500 F1: This option vests upon the termination of the Consulting Agreement effective November 4, 2024, by and between Renovaro Inc. and Tarsh PB Advisors LLC so long that a replacement CFO is hired as of such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests upon the termination of the Consulting Agreement effective November 4, 2024, by and between Renovaro Inc. and Tarsh PB Advisors LLC so long that a replacement CFO is hired as of such date.
Onconetix, Inc.
Report date August 15, 2025 · Filed August 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40 |
Reported balance
After 2025-08-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-08-15 · Other · Acquired 39 · Balance 40 F1: Represents a restricted stock award originally granted to the Reporting Person on September 26, 2024 pursuant to the Issuer's 2022 Equity Incentive Plan, as amended ("2022 Plan" and the grant on such date, the "Original Award"). On August 15, 2025, the Original Award was modified to change the vesting terms, such that the award, which was to vest in full on August 31, 2025, was changed to vest in full on August 31, 2026, so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date. Except as set forth herein, the Original Award remains unmodified. F2: On June 13, 2025, the Issuer effected a 1-for-85 reverse split of its Common Stock. The amounts set forth herein are presented on a post-split basis. |
| Common StockSEC Table I · non-derivative | Direct | 658 |
Reported balance
After 2025-08-15 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-08-15 · Grant · Acquired 618 · Balance 658 F3: Represents a restricted stock award granted to the Reporting Person pursuant to the 2022 Plan. The award will vest in full on August 31, 2026 so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock award originally granted to the Reporting Person on September 26, 2024 pursuant to the Issuer's 2022 Equity Incentive Plan, as amended ("2022 Plan" and the grant on such date, the "Original Award"). On August 15, 2025, the Original Award was modified to change the vesting terms, such that the award, which was to vest in full on August 31, 2025, was changed to vest in full on August 31, 2026, so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date. Except as set forth herein, the Original Award remains unmodified.
F2: On June 13, 2025, the Issuer effected a 1-for-85 reverse split of its Common Stock. The amounts set forth herein are presented on a post-split basis.
F3: Represents a restricted stock award granted to the Reporting Person pursuant to the 2022 Plan. The award will vest in full on August 31, 2026 so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2025 Filed Aug 19, 2025 16:05 UTC | Onconetix, Inc. ONCO · Entity 8471 | GrantCommon Stock | 618 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-078488 · ownership.xml · nonDerivative · entry 2 Tarsh Simon · CIK 0001943931 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 658 F3 · shares: Represents a restricted stock award granted to the Reporting Person pursuant to the 2022 Plan. The award will vest in full on August 31, 2026 so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 16:05 UTC | Onconetix, Inc. ONCO · Entity 8471 | OtherCommon Stock | 39 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-078488 · ownership.xml · nonDerivative · entry 1 Tarsh Simon · CIK 0001943931 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40 F1 · shares: Represents a restricted stock award originally granted to the Reporting Person on September 26, 2024 pursuant to the Issuer's 2022 Equity Incentive Plan, as amended ("2022 Plan" and the grant on such date, the "Original Award"). On August 15, 2025, the Original Award was modified to change the vesting terms, such that the award, which was to vest in full on August 31, 2025, was changed to vest in full on August 31, 2026, so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date. Except as set forth herein, the Original Award remains unmodified. F2 · shares: On June 13, 2025, the Issuer effected a 1-for-85 reverse split of its Common Stock. The amounts set forth herein are presented on a post-split basis. F2 · balance_after: On June 13, 2025, the Issuer effected a 1-for-85 reverse split of its Common Stock. The amounts set forth herein are presented on a post-split basis. Read SEC document |
| November 04, 2024 Filed Nov 6, 2024 16:34 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | GrantOption to purchase shares of common stock · Derivative | 58,500 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001731122-24-001725 · ownership.xml · derivative · entry 1 Tarsh Simon · CIK 0001943931 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,500 Underlying: Common stock · 58,500 shares Expires 2034-11-04 F1 · derivative.exercise_date: This option vests upon the termination of the Consulting Agreement effective November 4, 2024, by and between Renovaro Inc. and Tarsh PB Advisors LLC so long that a replacement CFO is hired as of such date. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 19:11 UTC | Onconetix, Inc. ONCO · Entity 8471 | GrantCommon Stock | 3,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-083524 · ownership.xml · nonDerivative · entry 1 Tarsh Simon · CIK 0001943931 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,477 F1 · shares: Represents a restricted stock award granted to the Reporting Person pursuant to the Issuer's 2022 Equity Incentive Plan, as amended. The award will vest in full on August 31, 2025 so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 15:50 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | GrantOption to purchase shares of common stock · Derivative | 10,000 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001731122-24-000425 · ownership.xml · derivative · entry 1 Tarsh Simon · CIK 0001943931 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-03-11 F1 · derivative.exercise_date: This option vests upon the termination of the Consulting Agreement effective March 11, 2024, by and between Renovaro Inc. and Tarsh PB Advisors LLC so long that a replacement CFO is hired as of such date. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 21:10 UTC | Onconetix, Inc. BWV · Entity 8471 | GrantCommon Stock | 6,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-045324 · ownership.xml · nonDerivative · entry 1 Tarsh Simon · CIK 0001943931 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,360 F1 · shares: Represents a restricted stock award granted to the Reporting Person pursuant to the Issuer's 2022 Equity Incentive Plan, as amended. The award will vest in full on May 31, 2024 so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 16:27 UTC | Onconetix, Inc. BWV · Entity 8471 | GrantStock Option · Derivative | 4,073 | $0.00 Strike: $3.48 | $0.00 |
DisclosureSEC source: 0001213900-22-050780 · ownership.xml · derivative · entry 1 Tarsh Simon · CIK 0001943931 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,073 Underlying: Common Stock · 4,073 shares Expires 2032-08-22 F1 · derivative.exercise_date: Stock options (the "Options") were granted to Mr. Tarsh on August 22, 2022. The Options vest and become exercisable in 9 monthly installments beginning on September 22, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.